Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2012
A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vanek Vincent W, Borum Peggy, Buchman Alan, Fessler Theresa A, Howard Lyn, Jeejeebhoy Khursheed, Kochevar Marty, Shenkin Alan, Valentine Christina J, Novel Nutrient Task Force, Parenteral Multi-Vitamin and Multi–Trace Element Working Group, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors
Аннотация
The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet the requirements for most patients who receive parenteral nutrition (PN). However, a separate parenteral vitamin D preparation (cholecalciferol or ergocalciferol) should be made available for treatment of patients with vitamin D deficiency unresponsive to oral vitamin D supplementation. Carnitine is commercially available and should be routinely added to neonatal PN formulations. Choline should also be routinely added to adult and pediatric PN formulations; however, a commercially available parenteral product needs to be developed. The parenteral multi-trace element (TE) preparations that are commercially available in the U.S. require significant modifications. Single-entity trace element products can be used to meet individual patient needs when the multiple-element products are inappropriate (see Summary/A.S.P.E.N. Recommendations section for details of these proposed modifications).